Discover 701 paid clinical trials in Killeen, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 701
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
for
Myasthenia Gravis
Location: Austin TX, Kansas City KS, O'Fallon IL, Iowa City IA,
Sponsor: argenx
Sex: All
Age: 18+
Code: NCT06298565
Recruiting
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
for
FSHD
Location: Austin TX, Dallas TX, Kansas City KS, Aurora CO,
Sponsor: University of Kansas Medical Center
Sex: All
Age: 0+
Code: NCT04635891
Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Location: Austin TX, San Antonio TX, Chattanooga TN,
Sponsor: argenx
Sex: All
Age: 18+
Code: NCT07294170
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Location: Austin TX, San Antonio TX, Chattanooga TN,
Sponsor: argenx
Sex: All
Age: 18+
Code: NCT07284420
Phase 2, Recruiting
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
for
Myasthenia Gravis
Location: Austin TX, Dallas TX, New Orleans LA, Cordova TN,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18 - 70+
Code: NCT07217587
Phase 3, Recruiting
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
for
Generalized Myasthenia Gravis
Location: Austin TX, Chicago IL, Philadelphia PA, Seattle WA
Sponsor: Amgen
Sex: All
Age: 2 - 17
Code: NCT06987539
Phase 2, Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor